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Introduction: Rheumatoid arthritis (RA) patients with autoantibodies against collagen type II (CII) are characterized
by acute RA onset with elevated inflammatory measures and early joint erosions as well as increased production
of tumor necrosis factor-α (ΤΝF-α) by peripheral blood mononuclear cells (PBMC) stimulated by anti-CII immune
complexes (IC) in vitro. Polymorphonuclear granulocytes (PMN) are abundant in RA synovial fluids, where they might
interact directly with anti-CII IC in the articular cartilage, but no studies have investigated PMN responses towards
anti-CII IC. The aim was to investigate whether PMN react towards anti-CII IC, and to what extent such reactivity
might relate to the clinical acute onset RA phenotype associated with elevated levels of anti-CII.
Methods: PMN and PBMC isolated from healthy donors were stimulated with IC made with a set of 72 baseline
patient sera (24 anti-CII positive, 48 anti-CII negative) chosen from a clinically well-characterized RA cohort with
two-year radiological follow-up with Larsen scoring. PMN expression of cluster of differentiation (CD)11b, CD66b,
CD16 and CD32 was measured by flow cytometry, whereas PMN production of myeloperoxidase (MPO) and
interleukin (IL)-17, and PBMC production of ΤΝF-α was measured with enzyme linked immunosorbent assay.
Results: PMN expression of CD11b, CD66b and MPO, and PBMC production of ΤΝF-α were upregulated whereas
PMN expression of CD16 and CD32 were downregulated by anti-CII IC. CD16, CD66b, and MPO production
correlated to serum anti-CII levels (Spearman’s ρ = 0.315, 0.675 and 0.253, respectively). CD16 was associated with
early joint erosions (P = 0.024, 0.034, 0.046 at baseline, one and two years) and CD66b was associated with changes
in joint erosions (P = 0.017 and 0.016, at one and two years compared to baseline, respectively). CD66b was
associated with baseline C-reactive protein and PBMC production of ΤΝF-α was associated with baseline erythrocyte
sedimentation rate, in accordance with our earlier findings. No clinical associations were observed for MPO or IL-17.
Conclusion: PMN responses against anti-CII IC are more closely associated with early joint erosions than are PBMC
cytokine responses. PMN reactivity against anti-CII IC may contribute to joint destruction in newly diagnosed RA
patients with high levels of anti-CII.* Correspondence: johan.ronnelid@igp.uu.se
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Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterized by joint pain and destruction. Colla-
gen type II (CII) is a major component of joint cartilage.
We have described a distinct acute-onset RA phenotype
characterized by high levels of collagen type II autoanti-
bodies (anti-CII) in serum and increased C-reactive
protein (CRP) levels and erythrocyte sedimentation rate
(ESR) at the time of diagnosis [1]. Shortly after diagnosis
RA patients’ anti-CII levels drop, as do levels of CRP
and ESR. Anti-CII-positive patients also have more joint
destructions and a shorter time from symptom onset to
clinical RA diagnosis, further arguing for a more acute
onset among these patients [1,2]. We have previously
described an in vitro model showing that anti-CII-
containing immune complexes (ICs) induce tumor necro-
sis factor alpha (ΤΝFα), interleukin (IL)-1β and IL-8 from
peripheral blood monocytes via Fc gamma receptor IIa
[3]. We hypothesized that these IC-induced cytokines
drive an early acute phase response and joint destruction,
and in agreement with this hypothesized that serum anti-
CII levels, in vitro ΤΝFα and IL-1β production, ESR, and
CRP show temporal associations in serially followed patients
with high baseline anti-CII levels [1].
The T-cell-dependent and B-cell-dependent collagen-
induced arthritis mouse model has substantiated the
possible importance of collagen immunity in RA [4].
The strictly humoral collagen antibody-induced arthritis
(CAIA) mouse model shows that anti-CII can initiate
arthritis [5,6]. CAIA has been induced in mice lacking
an adaptive immune system, showing a direct role of
anti-CII in arthritis development [7]. Our hypothesis is
that CAIA is a mouse model for the acute-onset anti-
CII-dependent RA phenotype.
Polymorphonuclear granulocytes (PMN) are found in
large numbers in synovial fluid in active RA. These
PMN are reactive and affect cytokine-signaling pathways
[8-11]. Although PMN normally are short lived and eas-
ily undergo apoptosis, in the synovial environment they
are influenced by cytokines and other factors increasing
survival [12,13]. Studies in juvenile idiopathic arthritis
implicate PMN in arthritis development [14-16]. During
inflammation, PMN respond by producing reactive oxi-
dative species and cytokines including IL-17 [17], releas-
ing myeloperoxidase (MPO) and other granule proteins,
and by regulating cell surface markers. PMN express Fc
gamma receptors including CD16 that bind ICs, generat-
ing intracellular signals through immunoreceptor-based
tyrosine motifs [18-22]. Other PMN surface molecules
such as CD11b and CD66b are effective in adhesion to
endothelium during inflammatory processes. CD66b is
upregulated by phorbol mysistate acetate or by N-for-
myl-methionyl-leucyl-phenylalanine in vitro, and is also
upregulated on RA PMN both in the circulation [23] aswell as in synovial fluid [24]. PMN communicate with the
adaptive immune system through chemokines such as
CXCL8 [25] and IL-17 [17,26,27]. IL-17 has been known
to be involved in the pathogenesis of autoimmune diseases
[28], and blockade of IL-17 modulated autoimmunity [29],
including arthritis [30].
PMN are also found in the pannus tissue, thus in close
contact with cartilage where anti-CII-containing ICs can
form and be involved in cartilage damage and joint de-
struction [31-33]. We therefore wanted to study PMN
functional reactivity towards anti-CII ICs. Experiments
were designed to study this hypothesized mechanism
initiated by the interaction of PMN with anti-CII IC,
and to address the role of PMN in the distinct anti-CII-
dependent acute-onset RA phenotype.
Methods
Patients and cell donors
RA patients were chosen from a cohort of 274 RA pa-
tients included from 1995 to 2000 at the Department of
Rheumatology, Karolinska University Hospital as described
previously [1]. All patients fulfilled the 1987 American
College of Rheumatology classification criteria [34]. From
this group a smaller set of 72 samples manageable for func-
tional studies were chosen. This group includes all 24 anti-
CII-positive patients in the full cohort, the 24 patients with
the lowest anti-CII (negative) and rheumatoid factor (RF)-
negative, and the 24 patients with the lowest anti-CII
(negative) and RF-positive (Table 1). The latter subdivision
was made to rule out any effects of RF on in vitro func-
tional responses to ICs, due to nonspecific IgG binding to
the wells that we have found mostly in anti-CII-negative
samples [3]. The baseline clinical presentation of the full
RA cohorts has been published before [1], and the pres-
ently investigated 72 patients are detailed in Table 1. Iden-
tical X-ray images of hands and feet were obtained at
baseline, 1 year, and 2 years, and were quantified in a
blinded manner by an experienced investigator (MCW)
using the Larsen erosion score as described earlier [2].
Changes in Larsen score were calculated by subtracting
either the baseline or the 1-year Larsen score from the
2-year or 1-year scores. Heparinized blood was collected
from healthy donors and laboratory staff at Uppsala
University Hospital. The regional ethical boards at Uppsala
University and Karolinska University Hospital approved
the research, and all patients and cell donors gave in-
formed consent.
Preparation of immune complex
Cytokine stimulation by solid phase IC was performed as
described previously [3]. Native human CII (Chondrex,
Redmond, WA, USA) was diluted to 10 μg/ml and 50 μl
were added to Maxisorb enzyme-linked immunosorbent
assay (ELISA) wells (Nunc, Roskilde, Denmark). After





















Mean age at onset
(years)
59.6 (14.4) 59.7 (15.0) 59.4 (30.5) NS 63.3 (13.7) NS
% females 76 (55/72) 79.2 (38/48) 70.8 (17/24) NS 66.7 (6/9) NS
Mean disease duration
at inclusion (months)








47 34/72 48 (23/48) 37.5 (9/24) NS 33.3 (3/9) NS
CRP (mg/l) 31 (40) 20 (18) 53 (60) 0.020 46 (34) 0.007




2.1 (0.8) 2.0 (0.8) 2.3 (0.6) NS 2.4 (0.5) NS
Number of swollen
joints
10 (5) 8 (5) 12 (6) 0.022 10 (5) NS
Number of tender
joints
9 (5) 9 (5) 8 (6) NS 8 (3) NS
DAS28 5.1 (1.1) 5.0 (1.0) 5.2 (1.3) NS 5.5 (0.9) NS
Global VAS 43 (27) 45 (27) 39 (28) NS 46 (29) NS
Pain VAS 45 (23) 49 (23) 38 (21) NS 37 (21) NS
HAQ 0.99 (0.59) 0.97 (0.58) 1.02 (0.61) NS 1.33 (0.55) NS
Baseline Larsen score 9.71 (10.42) 9.36 (10.69) 10.37 (10.05) NS 12.28 (6.52) NS (0.12)
% of patients starting
DMARD therapy at
baseline
92 (66/72) 96 (46/48) 83 (20/24) NS 89 (8/9) NS
Data presented as means values (standard deviation) and as percentages (ratios). Differences between anti-CII-negative and anti-CII-positive patients are analyzed
using Mann–Whitney’s U test, whereas differences between proportions are analyzed using the chi-square test or Fisher’s exact test when appropriate. Data for
anti-CCP and RF have been published earlier [35,36]. Data for RF at the time of diagnosis are missing for one patient. Significant values are in bold. We have
deliberately expressed mean values to allow comparison with previously published data on the full RA cohort ([3]; n = 274). anti-CCP2, cyclic citrullinated
peptide version 2 antibodies; anti-CII, collagen type II autoantibodies; AU, arbitrary units; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints;
DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; NS, nonsignificant; RA, rheumatoid
arthritis; RF, rheumatoid factor; VAS, visual analog scale.
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human serum albumin for 1 hour. Thereafter 50 μl of 10%
patient sera diluted in phosphate-buffered saline were
added for 2 hours at room temperature for stimulation of
peripheral blood mononuclear cells (PBMC), whereas un-
diluted sera were used to prepare surface-bound IC for
stimulation of PMN. After washing, 300 μl responder
PBMC (106/ml) and PMN (106/ml) respectively were
added to the plates that were left to incubate for 20 hours
in a cell incubator, and then cells were harvested for flow
cytometry and supernatants for measurement of soluble
substances. To prepare ICs, new serum aliquots never
thawed or thawed/frozen only once were obtained from
the Karolinska biobank. A serum from the same RA pa-
tient that had been used to establish the standard curve inthe anti-CII ELISA was used in making anti-CII IC used
in the initial experiments defining PMN responses.
Cell purification
In initial experiments, PMN were purified from sodium
heparinized blood (Greiner bio-one GmbH, Kremsmünster,
Austria) with Ficoll (GE Healthcare, Uppsala, Sweden) after
osmotic lysis of the red blood cells. In later experiments,
PMN were isolated by Percoll (GE Healthcare) gradients
with 72% Percoll at the bottom and 63% Percoll at the top.
In this method the PMN were obtained between the two
Percoll gradients. PBMC were initially isolated by Ficoll as
done in our earlier studies [3] and in later experiments
from the upper part of the Percoll gradient described above.
The cell count and viability was checked with Türk’s
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chamber. The purity and viability obtained from the two
cell separation protocols were comparable. Both the PMN
and PBMC had purity above 96% and viability above 94%
(PBMC) and 91% (PMN).
Human collagen type II IgG ELISA
Data on anti-CII antibody levels were obtained from our
previous studies [1]. Patient samples above the 95th per-
centile among controls (29 arbitrary units (AU)/ml) were
regarded as positive [1]. In some experiments, known
concentrations of polyclonal IgG where the source was a
pharmaceutical preparation intended for intravenous im-
munoglobulin therapy (Privigen; CSL Behring, Stockholm,
Sweden) were serially diluted, coated on ELISA plates and
used as a standard curve to translate the concentration of
anti-CII from arbitrary units per milliliter to micrograms
of anti-CII IgG per milliliter. Privigen-coated ELISA wells
were also used to stimulate PBMC and PMN in parallel to
anti-CII IC stimulation, to allow comparison of the func-
tional effect of anti-CII IgG with mixed human IgG.
Cell stimulation
ELISA plates were coated with native human CII (10 μg/
ml) (ELISA grade; Chondrex Inc.) at 4°C overnight. The
anti-CII IC was prepared by adding RA sera to the CII-
coated ELISA plates during 2 hours of incubation on a
shaker at room temperature.
In a first set of experiments, aimed at defining appro-
priate measures for a clinical study, PMN isolated from
eight healthy donors were subjected to IC stimulation
with a serum with high concentration of anti-CII in IC
(14740 AU/ml or 8 μg/ml) or with an anti-CII-negative
healthy control serum. In the second experiment, where
functional responses were related to clinical outcome,
PMN and PBMC obtained from a single donor was
stimulated with anti-CII IC prepared with sera from 72
RA patients.
PBMC were stimulated with anti-CII IC prepared with
50 μl sera diluted 1:10 in each ELISA well as in previous
studies [3]. Initial experiments showed that PMN needed
higher antibody IgG concentrations for functional re-
sponses, and therefore undiluted sera were used in
otherwise identical ICs to stimulate PMN. Cells for flow
cytometry and supernatants for cytokine and MPO
measurements were harvested after 18 hours in a cell
incubator, a time determined as optimal for the investi-
gated the CD markers.
Flow cytometry analysis
Flow cytometry analysis was carried out with fluorescein
isothiocyanate-conjugated IgG1 antibodies against CD11b
(Bear1; Beckman Coulter, Marseille, France), CD66b
(80H3; Beckman Coulter), CD16 (DJ130c; DAKO, Glostrup,Denmark), and phycoerythrin-conjugated antibodies against
CD32 (2E1; Beckman Coulter). After addition to cells,
tubes were kept for 30 minutes at 4°C before washing
and fixing with 1% paraformaldehyde. Color compensa-
tion of phycoerythrin and fluorescein isothiocyanate
was done with anti-mouse immunoglobulin, κ/negative
control compensation particle set (BD Biosciences. Non-
specific binding was checked with IgG1 isotype controls
(Beckman Coulter). Analyses were performed with a BD
FACSCanto II flow cytometer and FACSDIVA software
(BD Biosciences).
Cytokine and myeloperoxidase measurements
Cytokine measurements were carried out with the ELISA
protocol used in previous studies [1,3]. All antibodies and
cytokine standards were from R&D Biosciences (Abingdon,
UK). For ΤΝFα measurement, the capture antibody
was mouse monoclonal MAB610, (2.0 μg/ml) and the
detection antibody was biotinylated polyclonal goat
antibody BAF210 (0.1 μg/ml). For IL-17, the Duo-set
kit was employed, using recommended antibody con-
centrations. MPO was analyzed using an ELISA kit
from Diagnostic AB (Uppsala, Sweden) and performed
according to the instructions from the manufacturer.
Statistical analysis
Because we have shown previously that anti-CII levels are
non-normally distributed [2], we uniformly used nonpara-
metric statistics. Groups were compared using the Mann–
Whitney U test, paired investigations were done with the
Wilcoxon signed-rank test, and correlations were calculated
with Spearman’s rank correlation test. When changes in re-
sponses against anti-CII ICs were calculated, the responses
in anti-CII-coated wells treated with a normal human (anti-
CII-negative) serum were subtracted from the responses
against anti-CII IC. There are no common rules for how to
evaluate association between functional responses (CD16,
CD66b, ΤΝFα, MPO) and clinical measures presented in
Table 2, so these responses were initially evaluated with
different cutoff values corresponding to the 50th to 95th
percentiles of the maximal responses. The 85th percentile
was uniformly found to be the most discriminatory cutoff
point for all responses, numerically delimiting a fraction of
patients corresponding to those with very high anti-CII
levels. All calculations were performed with Graphpad
prism 6 and JMP 9.0 software. P <0.05 was considered sig-
nificant. No correction for mass significance was done.
Results
Polymorphonuclear granulocytes respond to
anti-CII-containing surface-bound immune complex
by changes in expression of CD markers
PMN cell surface CD11b and CD66b were upregulated
and CD16 and CD32 were downregulated by anti-CII IC
Table 2 Association between, on one hand, in vitro granulocyte responses, PBMC responses and baseline antibody
levels and, on the other, baseline inflammatory markers, Larsen score and changes in Larsen score during the first
2 years after RA diagnosis







1 – 0 years
Δ Larsen score
2 – 0 years
Δ Larsen score
2 – 1 years
CD16
(PMN)
35/16.5 (0.08) 35.5/19.5 (0.26) 14.4/5.5 (0.024) 22.5/11.0 (0.034) 24.0/31.1 (0.046) 7.3/3.0 (0.08) 9.0/6.3 (0.88) 3.0/2.3 (0.27)
CD66b
(PMN)
49/14 (0.004) 33/19 (0.063) 13.5/6.0 (0.15) 22.0/11.0 (0.071) 24.0/13.2 (0.059) 7.5/2.6 (0.017) 10.4/5.2 (0.016) 5.1/2.3 (0.012)
MPO
(PMN)
14/18 (0.6) 19/21 (0.61) 5.4/7.0 (0.69) 17.0/11.0 (0.99) 17.7/13.2 (0.97) 6.9/2.8 (0.27) 9.6/5.3 (0.41) 2.5/2.3 (0.37)
ΤΝFα
(PBMC)
28/17 (0.18) 43/19 (0.049) 9.3/6.3 (0.57) 11.6/11.8 (0.75) 15.3/13.2 (0.52) 5.6/3.0 (0.50) 9.4/5.3 (0.43) 2.9/2.3 (0.48)
Anti-CII 36.5/14 (0.012) 29/19 (0.10) 11.5/6.3 (0.75) 16.0/11.0 (0.44) 15.0/13.5 (0.44) 4.3/3.6 (0.21) 8.1/5.3 (0.22) 2.6/2.3 (0.29)
Anti-CCP 15/18.5 (0.20) 23/20 (0.57) 6.8/7.0 (0.76) 13.0/10.5 (0.76) 15.8/12.0 (0.42) 4.6/2.5 (0.41) 8.3/5.3 (0.12) 3.0/1.5 (0.024)
RF 15/18 (0.65) 23/20 (0.66) 6.0/7.9 (0.17) 11.0/12.0 (0.52) 14.0/13.5 (0.64) 4.4/3.6 (0.71) 6.3/7.0 (0.44) 3.0/1.8 (0.049)
Data presented as median level for patients with significant change/not significant change in the parameter shown in the left column. Statistics were performed
with the Mann–Whitney U test. P values are shown within parentheses; significant values are in bold. anti-CII, collagen type II autoantibodies; anti-CCP, cyclic
citrullinated peptide antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MPO, myeloperoxidase; PBMC, peripheral blood mononuclear cells;
PMN, polymorphonuclear granulocytes; RA, rheumatoid arthritis; RF, rheumatoid factor; TNFα, tumor necrosis factor alpha.
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in parallel, the median change in mean fluorescence in-
tensity was +141% for CD11b, +165% for CD66b, –41%
for CD16 and –17% for CD32 (Figure 1). All eight PMN
preparations displayed the same pattern of response for
each CD marker. Directly coated IgG induced changes
similar to those of anti-CII IC (data not shown). From
these experiments and initial titrations performed with
various concentrations of anti-CII IC, CD66b and CD16
were proven to be the most sensitive markers of PMN
reactivity and were henceforth used in our clinical co-
hort study.
Comparison between stimulatory effects of surface bound
anti-CII immune complex and directly coated IgG
When the concentrations of anti-CII IgG in the anti-CII
IC were aligned to known concentrations of human IgG
bound to identical ELISA plates, we found a similar pat-
tern of slope for both systems (Figure 2a). The concentra-
tion of anti-CII IgG was determined to be 8 μg/ml IgG
anti-CII in the serum used in the experiments shown in
Figure 1. This level corresponds to 14,740 AU anti-CII/ml
in our previous publications [1-3]. From our earlier studies
we know that ΤΝFα production was dependent on anti-
CII concentrations [3]. We found that changes in PMN
CD marker expression required a higher concentration of
anti-CII than ΤΝFα responses from PBMC (Figure 2b vs.
Figure 2c,d). When PBMC ΤΝFα responses against anti-
CII IC were compared with directly coated IgG, there was
a left shift in the slope of ΤΝFα response against anti-CII
IC, implying that the responder cells needed lower
amounts of anti-CII in the form of surface-bound IC
than directly bound IgG to respond with comparable
TNF production (Figure 2b). Similar left shifts were alsoobserved for PMN expression of CD16 and especially
CD66b (Figure 2c,d).
Polymorphonuclear granulocyte responses to anti-CII
immune complex correlate with anti-CII levels
in RA patients
Anti-CII IC-induced changes in PMN CD markers showed
a strong correlation to anti-CII levels in the sera used to
prepare the anti-CII IC. Expression of CD66b showed
strong correlation (Spearman’s ρ = 0.675; P <0.0001), similar
to PBMC ΤΝFα responses (ρ = 0.585; P <0.0001). Changes
in PMN CD16 levels showed a negative correlation to anti-
CII levels (ρ =–0.315; P <0.0001). Supernatant MPO levels
showed a weaker correlation with anti-CII levels (ρ = 0.253,
P <0.039; Figure 3). We found low supernatant IL-17 levels,
without any correlation to anti-CII (data not shown). There
were no differences in any functional measure between ICs
prepared with sera from anti-CII-negative patients with and
without RF (data not depicted).
Polymorphonuclear granulocyte responses to anti-CII
immune complex associate with acute phase reactants
and radiological destruction during 2 years after
RA diagnosis
In agreement with our earlier studies, baseline serum anti-
CII levels and PBMC-derived ΤΝFα responses against
anti-CII IC associated with baseline CRP and ESR, respect-
ively (Table 2).
PMN cell surface levels of CD66b associated with base-
line CRP, with a similar trend for CD16. Reductions in
CD16 expression on PMN associated with Larsen score at
baseline, 1 year, and 2 years, whereas elevated CD66b ex-
pression was associated with a higher destruction rate be-
tween all investigated time points. Serum anti-CII levels
Figure 1 Granulocyte expression of CD11b, CD66b, CD16, and CD32. Granulocyte expression of (a) CD11b, (b) CD66b, (c) CD16, and (d)
CD32 after 18 hours of stimulation with surface-bound collagen type II autoantibody (anti-CII) immune complex (IC) prepared with a high-level
anti-CII serum or with normal human serum. Eight healthy donors provided the cells. Horizontal bars, median values. Statistical comparisons were
made with the paired Wilcoxon signed-rank test. CII, collagen type II; MFI, mean fluorescence intensity; NHS, normal human serum.
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tions with radiological destruction (Table 2).
Discussion
In previous studies we have shown that anti-CII IC can
stimulate PBMC monocytes in vitro to produce proin-
flammatory cytokines, and that these responses are asso-
ciated with inflammatory measures and joint erosions at
the time of early serum sampling. The in vitro function
of these antibodies thus corresponds to the clinical pheno-
type in a time-dependent manner, arguing that this
in vitro system mimics one tentative pathogenic mechan-
ism in vivo in the subset of RA patients with elevated
serum anti-CII levels at the time of diagnosis [1-3]. In the
present study we have used an analogous model to study
PMN reactivity towards anti-CII ICs, using the subset of
patients representing the highest and lowest anti-CII levels
in a larger previously published serological study [1].
Changes in PMN cell surface markers CD66b and CD16associate with acute-onset inflammation and especially
with joint destruction during the first 2 years after RA
diagnosis. Notably, the association with joint destruction
was stronger than for PBMC responses recorded as ΤΝFα
production in response to parallel anti-CII ICs. In agree-
ment with our previously published studies on the full co-
hort, anti-CII serum levels and PBMC-derived ΤΝFα
associated with baseline CRP and ESR, whereas anti-cyclic
citrullinated peptide version 2 (CCP2) and RF associated
with an increased rate of cartilage destruction after 2 years,
again arguing that the anti-CII-associated acute-onset RA
phenotype differs from the bad long-term prognosis asso-
ciated with the traditional serological markers RF and
anti-CCP2 [1,35,36].
The CAIA mouse arthritis model has demonstrated that
anti-CII can initiate acute polyarthritis associated with
PMN activation leading to endothelial cell adhesion and
recruitment of these PMN to inflamed tissue. The effect
was diminished by antileukoproteinase, a PMN serine
Figure 2 (See legend on next page.)
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Figure 2 Functional reactivity against IgG as part of surface-bound collagen type II autoantibody (anti-CII) immune complex and polyclonal
IgG. Amounts and functional reactivity against IgG as part of surface-bound collagen type II autoantibody (anti-CII) immune complex and polyclonal IgG
directly coated to identical enzyme-linked immunosorbent assay (ELISA) plates. (a) ELISA reactivity of IgG against type II collagen (CII) aligned to known
concentrations of directly coated IgG; these anti-CII levels (μg/ml) were thereafter used in the comparisons below. (b) Peripheral blood mononuclear cell-
derived tumor necrosis factor alpha (ΤΝFα). (c), (d) Polymorphonuclear granulocyte expression of CD66b and of CD16 respectively were compared for
different concentrations of anti-CII and polyclonal IgG. Panels depict one representative result out of two to four experiments performed for each com-
parison. MFI, mean fluorescence intensity; OD, optical density.
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volved in the process [37,38]. CAIA is an acute-onset arth-
ritis model, where joint symptoms appear during 8 to
12 days after booster lipopolysaccharide injection [39].
We believe that the anti-CII-associated acute-onset RA
phenotype is the human counterpart to CAIA in mice,
and that the anti-CII IC in vitro models we have used in
this article and in previous papers explain (some of) theFigure 3 Correlation between functional responses against collagen a
levels in 72 early rheumatoid arthritis patients. (a), (b) Data for polymo
polymorphonuclear granulocyte supernatant levels of myeloperoxidase (MP
necrosis factor alpha (ΤΝFα). Twenty-four of the patients have collagen type I
group. The 48 anti-CII-negative patients chosen were those with the lowest a
rheumatoid factor (n = 24) in the full rheumatoid arthritis cohort (n = 274). Sta
arbitrary units; MFI, mean fluorescence intensity; NS, nonsignificant.pathogenic mechanisms responsible for the characteristics
of this RA phenotype.
When we normalized the IgG levels in anti-CII ICs to
concentrations of human IgG directly coated to ELISA
wells, we found that anti-CII ICs were more efficient in
stimulating both PBMC and PMN (Figure 2). This was
found in repeated experiments. One obvious hypothetical
difference is the orientation of the Fc fragments whereutoantibody immune complex and serum collagen autoantibody
rphonuclear granulocyte CD66b and CD16 expression. (c), (d) Data for
O) and peripheral blood mononuclear cell supernatant levels of tumor
I autoantibody (anti-CII), nine of which represent the very high outlier
nti-CII levels detectable with rheumatoid factor (n = 24) and without
tistics performed with the Spearman rank correlation test. AU,
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expose their Fc fragments upwards towards Fc receptors
of added responder cells, whereas direct coating can result
in stochastic orientation. The positioning of autoantibody
epitopes within the native CII molecule might also affect
the functional outcome, in analogy with an earlier report
showing that a combination of four monoclonal anti-CII
antibodies with closely positioned epitopes within the CII
molecule is arthritogenic, whereas other antibody combi-
nations are not [40]. The degree of IgG glycosylation is
also tentatively important, as IgG lacking galactosyl resi-
dues had defects in binding to Fc gamma receptors
[41-43]. Current studies on these discrepant findings are
ongoing. The issue is not trivial because the CII-coated
surface system had a weak autostimulatory response on
PBMC ΤΝFα production (Figure 2b) and resulted in a
higher baseline CD16 expression than directly coated IgG
(Figure 2d). Addition of polymyxin B to the anti-CII IC
did not change the difference between the two surfaces in
stimulating ΤΝFα levels or expression of CD markers,
arguing against a lipopolysaccharide-mediated effect.
These differences between surfaces, however, do not in-
fluence the outcome of the present RA cohort study,
where all clinical comparisons were made with anti-CII
IC-induced responses.
Cell stimulatory responses in vivo are probably associ-
ated with the availability of anti-CII IC for cells in the
synovial fluid. Investigations by Holmdahl and colleagues
have shown that anti-CII can adhere to intact joint
cartilage after intraperitoneal or intravenous injection
[44,45], but these studies do not explain how such ICs
will be in contact with responder cells in the synovial
fluid. Studies from Jasin and colleagues indicate that
binding of CII antibodies to an intact cartilage surface is
dependent on neutrophil elastase-induced damage of the
thin layer of small proteins covering the intact joint
cartilage [46-48]. This disruption of the covering layer is
transient, and is restored already after 10 days in a rabbit
model [49], a time span in agreement with our previous
findings that elevated anti-CII levels are associated with
laboratory signs of inflammation at the time of RA diag-
nosis, but not 3 months later [1].
Although primarily associated with the Th17 T-cell
subset, IL-17 can also be produced from innate im-
mune cells, including PMN [17,26,27]. However, in this
investigation we found very low levels of IL-17 induced
by anti-CII IC-stimulated PMN, using an ELISA de-
tecting IL-17A produced by PMN. MPO levels in the
same supernatants, however, were high and correlated
to anti-CII levels, although we could not show any as-
sociation with the clinical phenotype as for the PMN
CD markers.
Besides activating PMN in the joint space and synovial
tissue, anti-CII containing ICs can also attract newPMN to enter the inflammatory area. The classical ex-
planation is complement activation, as has been shown for
anti-citrullinated protein/peptide antibody (ACPA) where
low-avidity antibodies are associated both with strong
complement activation and higher rate of joint destruction
[50]. Besides creating chemotactic intermediates such as
anaphylatoxin C3a and especially C5a, iC3b produced
after IC-induced classical complement activation and co-
valently bound to surfaces close to ICs will bind PMN via
complement receptors. Another explanation is the chemo-
tactic action of PMN-attracting chemokines, notably IL-8/
CXCL8. We have earlier shown that PBMC monocytes
produce IL-8 in response to anti-CII IC [3], and these
findings are currently being investigated further in the
context of PMN.
In the present study, due to practical cell culture limi-
tations, we only analyzed a fraction (n = 72) of patients
in the previous study (n = 274). Anti-CII levels in RA
patients show a discrete small outlier group of individ-
uals with very high anti-CII levels that is clearly sepa-
rated from the remaining patients (see Figure 1 in [2]),
and the anti-CII-negative patients chosen were those
with the lowest anti-CII levels in the cohort, so the
graphs in Figure 3 show three seemingly separate groups
of patients.
This paper extends our previous studies of collagen
antibodies and their functional association with a clin-
ical RA phenotype with acute onset, to also encompass
a tentative pathogenetic role of PMN in this phenotype.
Because the corresponding autoantigen is clearly joint
specific, we believe that the strong temporal association
between the occurrence of anti-CII, their functional
roles in vitro in stimulating PBMC monocytes [3] and
PMN, and the temporally associated clinical RA pheno-
type are rather strong arguments that anti-CII is associ-
ated with events having mechanistic similarities with
the anti-CII-induced CAIA model in rodents. In the
same cohort in which we showed this association [2,3],
we previously have investigated the prognostic impact
of anti-CCP2 [36]. In that study, median anti-CCP2 levels
dropped to approximately 60% of baseline levels in the
first year in the anti-CCP2-positive patients, and stayed
low during the 5-year follow-up, at the same time as the
anti-CCP2-positive patients showed progressively worse
outcome, especially concerning swollen joint counts and
Disease Activity Score in 28 joints. Other studies have also
shown these temporally divergent patterns with decreasing
ACPA levels in parallel to clinical worsening for ACPA-
positive RA patients compared with ACPA-negative RA
patients [51]. The fact that changes in ACPA levels lack
association with the appearance of the ACPA-associated
clinical RA phenotype, as is the case for anti-CII, should
be considered in attempts to link ACPA functions in vitro
to RA pathogenesis.
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We have investigated the role of PMN in the acute-
onset RA phenotype associated with anti-CII. Our re-
sults imply that PMN responses against anti-CII ICs are
more closely associated with early joint erosions than
are PBMC cytokine responses. This implicates a promin-
ent pathogenic role of PMN in the joint destruction seen
at the time of diagnosis in patients with the acute-onset
RA phenotype characterized by high levels of anti-CII.
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